NEWTOWN, PA — Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced new preclinical data characterizing rigosertib’s mechanisms of action in a poster at the American Association for Cancer Research Special Conference on Targeting RAS (AACR Targeting RAS Conference).
“The preclinical results presented at the Targeting RAS Conference increase our understanding of rigosertib’s anti-cancer effects and thereby represent a valuable tool to inform its continued clinical development,” said Mark Gelder, M.D., Chief Medical Officer of Onconova. “I am particularly encouraged by data showing rigosertib-induced activation of the NLRP3 inflammasome. These data provide additional support for previously reported clinical results in KRAS-mutated non-small cell lung cancer that suggest rigosertib can synergize with checkpoint inhibition to drive clinical response in patients with various KRAS mutations that failed prior checkpoint inhibitor therapy. Data identifying potential targets through which rigosertib inhibits RAS-MAPK signaling are also compelling, as this pathway plays a key role in the formation and growth of a variety of cancers. Collectively, these data provide a mechanistic rationale for the differentiated potential of rigosertib when compared to the FDA approved agents that target only the KRAS G12C mutation.”
Preclinical studies featured in the poster evaluated mechanisms by which rigosertib may activate an anti-cancer immune response and inhibit the RAS-MAPK pathway. Results indicate that rigosertib stimulates an immune response via activation of the NLRP3 inflammasome, which leads to the secretion of the pro-inflammatory cytokines IL-1β and IL-18. Additional data identified the proteins NQO2, ERO1A, and NEK7 as potential novel targets that may be modulated by rigosertib. Activation of NQO2 and/or ERO1A leads to reactive oxygen species (ROS)-induced activation of JNK signaling, which in-turn leads to RAS-MAPK pathway inhibition. Rigosertib interaction with NEK7 could possibly cause the destabilization of microtubules and cell cycle arrest in mitosis, which are critical for cell division.
A copy of the poster, titled “CETSA Profiling Unveils Novel Targets Engaged by Anti-tumor Drug Rigosertib to Inhibit RAS-MAPK Signaling and Trigger NLRP3 Inflammasome Activation,” is available on the “Scientific Presentations” section of the Onconova website.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.
Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.